Adverse events reporting | Prescribing information ( This product is under additional monitoring)

Dosing and Administration

TREMFYA® has a convenient dosing regimen, with 6 doses per year in PsA and Pso1

Dosing and administration chart

For PsA patients at high risk for joint damage according to clinical judgement, a dose of 100 mg every 4 weeks may be considered1

In PsA clinical studies, an increased incidence of liver enzyme elevations was observed in patients treated with TREMFYA® q4w compared to patients treated with TREMFYA® q8w or placebo. When prescribing TREMFYA® q4w in psoriatic arthritis, it is recommended to evaluate liver enzymes at baseline and thereafter according to routine patient management. If increases in ALT or AST are observed and drug-induced liver injury is suspected, TREMFYA® should be temporarily interrupted until this diagnosis is excluded1


TREMFYA® offers patients simple, flexible dosing1

"How to use" video Tremfya is suitable for patients and caregivers. It includes helpful information on preparing and self-administrating TREMFYA® injections

TREMFYA® provides self-administration via One-Press – a device highly accepted by patients2

98.4% of patients starting on TREMFYA® were satisfied or very satisfied with their self-injections with One-Press at Week 122

Adverse events should be reported. This medicinal product is subject to additional monitoring and it is therefore important to report any suspected adverse events related to this medicinal product. Healthcare professionals are asked to report any suspected adverse events via: HPRA Pharmacovigilance Website: www.hpra.ie. Adverse events should also be reported to Janssen Sciences Ireland UC on 1800 709 122 or at dsafety@its.jnj.com.
  1. Ferris L, et al. J Derm Treat 2020;31:152-159.
CP-310758 - July 2022